


In the Claims:

1. (Previously Presented) A compound of the formula (I)



in which

A is an aromatic heteromonocyclic, or an aromatic or partially aromatic heterobicyclic ring,

where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups, where not more than one of the heteroatoms is an oxygen atom,

and A may be substituted by radicals  $R^{11}$ ,  $R^{12}$  and/or  $R^{13}$ ,

where

$R^{11}$ ,  $R^{12}$  and  $R^{13}$  at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , OH, O- $C_1$ - $C_4$ -alkyl, O-phenyl, O- $C_1$ - $C_4$ -alkylen-phenyl, phenyl,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $NH_2$ ,  $NH(C_1$ - $C_4$ -alkyl) and  $N(C_1$ - $C_4$ -alkyl) $_2$ ,

$R^3$  and  $R^4$  are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , OH, O- $C_1$ - $C_4$ -alkyl, O-phenyl, O- $C_1$ - $C_4$ -alkylen-phenyl, phenyl,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $NH_2$ ,  $NH(C_1$ - $C_4$ -alkyl) and  $N(C_1$ - $C_4$ -alkyl) $_2$ , or

$R^3$  and  $R^4$  are connected to give -CH=CH-CH=CH-, -(CH $_2$ ) $_4$ - or -(CH $_2$ ) $_3$ -,

R<sup>5</sup> is a radical (W)-(X)-(Y)-Z, where

W is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub>-alkylen, C<sub>2</sub>-C<sub>4</sub>-alkenylen, C<sub>2</sub>-C<sub>4</sub>-alkynylen, O, O-(C<sub>1</sub>-C<sub>4</sub>-alkylen), S, S-(C<sub>1</sub>-C<sub>4</sub>-alkylen), NR<sup>54</sup>, NR<sup>54</sup>-(C<sub>1</sub>-C<sub>4</sub>-alkylen) and a bond,

X is selected from the group consisting of CO, CO-O, SO<sub>2</sub>, NR<sup>54</sup>, NR<sup>54</sup>-CO, NR<sup>54</sup>-SO<sub>2</sub>, CO-NR<sup>58</sup> and a bond,

Y is C<sub>1</sub>-C<sub>6</sub>-alkylen, C<sub>2</sub>-C<sub>6</sub>-alkenylen, C<sub>2</sub>-C<sub>6</sub>-alkynylen, or a bond,

Z is selected from the group consisting of hydrogen, E, O-R<sup>52</sup>, NR<sup>51</sup>R<sup>52</sup>, S-R<sup>52</sup>, where

E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, said ring may comprise up to two oxo groups, and may be substituted by radicals R<sup>55</sup>, R<sup>56</sup>, R<sup>57</sup>, and/or up to three radicals R<sup>53</sup>,

R<sup>51</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl and C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R<sup>53</sup>,

R<sup>52</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, E and C<sub>1</sub>-C<sub>4</sub>-alkylen-E,

R<sup>53</sup> at each occurrence is independently selected from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

R<sup>54</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl and C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R<sup>59</sup>,

R<sup>55</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl, C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the ring may be substituted by up to two radicals R<sup>60</sup>, and OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, O-phenyl, O-C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

R<sup>56</sup> is a group Q<sup>1</sup>-Q<sup>2</sup>-Q<sup>3</sup>, where

Q<sup>1</sup> is selected from the group consisting of a bond, C<sub>1</sub>-C<sub>4</sub>-alkylen, C<sub>2</sub>-C<sub>4</sub>-alkenylen, C<sub>2</sub>-C<sub>4</sub>-alkynylen, C<sub>1</sub>-C<sub>4</sub>-alkylen-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), N(C<sub>1</sub>-C<sub>4</sub>-alkyl), C<sub>1</sub>-C<sub>4</sub>-alkylen-NH, NH, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-C<sub>1</sub>-C<sub>4</sub>-alkylen, NH-C<sub>1</sub>-C<sub>4</sub>-alkylen, O, C<sub>1</sub>-C<sub>4</sub>-alkylen-O, O-C<sub>1</sub>-C<sub>4</sub>-alkylen, CO-NH, CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO, CO, SO<sub>2</sub>, SO, S, O, SO<sub>2</sub>-NH, SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-SO<sub>2</sub>, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-SO<sub>2</sub>, O-CO-NH, O-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO-O, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-O, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-NH, and NH-CO-NH,

Q<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub>-alkylen, C<sub>2</sub>-C<sub>4</sub>-alkenylen, C<sub>2</sub>-C<sub>4</sub>-alkynylen, and a bond,

Q<sup>3</sup> is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups and may be substituted by the radicals R<sup>63</sup>, R<sup>64</sup> and/or R<sup>65</sup>,

R<sup>57</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, phenyl, C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, COOH, CO-O-C<sub>1</sub>-C<sub>4</sub>-alkyl, CONH<sub>2</sub>, CO-NH-C<sub>1</sub>-C<sub>4</sub>-alkyl, CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>, CO-C<sub>1</sub>-C<sub>4</sub>-alkyl, CH<sub>2</sub>-NH<sub>2</sub>, CH<sub>2</sub>-NH-C<sub>1</sub>-C<sub>4</sub>-alkyl and CH<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

R<sup>58</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl and C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R<sup>62</sup>,

R<sup>59</sup>, R<sup>60</sup> and R<sup>62</sup> at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

R<sup>63</sup>, R<sup>64</sup> and R<sup>65</sup> at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, O-phenyl, O-C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, phenyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

$R^6$  and  $R^7$  are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , OH, O- $C_1$ - $C_4$ -alkyl, O-phenyl, O- $C_1$ - $C_4$ -alkylen-phenyl, phenyl,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $NH_2$ ,  $NH(C_1$ - $C_4$ -alkyl) and  $N(C_1$ - $C_4$ -alkyl) $_2$ ,

5

and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof.


2. (Previously Presented) The compound of claim 1, wherein A is selected from the group consisting of aromatic heteromonocyclic and aromatic heterobicyclic systems comprising 1 or 2 heteroatoms, where one of the 2 heteroatoms is nitrogen.

10

3. (Previously Presented) The compound of claim 1, wherein A is selected from the group consisting of benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline, quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene, benzofuran and furan.

15

4. (Previously Presented) A compound of the formula (II)



20 in which

B is selected from the group consisting of thiophene, furan, pyrrole, pyridine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, dihydrobenzofuran, indole, dihydroisoindole,

25

an aromatic heteromonocyclic and an aromatic or partially aromatic heterobicyclic ring,

where the heterocycles are 5- or 6-membered rings and comprise 2 to 4 heteroatoms

selected from the group consisting of N, O and S, and up to 2 oxo groups, and

B may be substituted by the radicals  $R^{21}$ ,  $R^{22}$  and/or  $R^{23}$ ,

5  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , OH, O- $C_1$ - $C_4$ -alkyl, O-phenyl, O- $C_1$ - $C_4$ -alkylen-phenyl, phenyl,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $NH_2$ ,  $NH(C_1-C_4-alkyl)$  and  $N(C_1-C_4-alkyl)_2$ , morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-piperazin-1-yl, 4-( $C_1$ - $C_4$ -alkyl)-piperazin-1-yl,

10  $R^3$  and  $R^4$  are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , OH, O- $C_1$ - $C_4$ -alkyl, O-phenyl, O- $C_1$ - $C_4$ -alkylen-phenyl, phenyl,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $NH_2$ ,  $NH(C_1-C_4-alkyl)$  and  $N(C_1-C_4-alkyl)_2$ , or

15  $R^3$  and  $R^4$  are connected to give  $-CH=CH-CH=CH-$ ,  $-(CH_2)_4-$  or  $-(CH_2)_3-$ ,

$R^5$  is a radical (W)-(X)-(Y)-Z, where

20 W is selected from the group consisting of  $C_1$ - $C_4$ -alkylen,  $C_2$ - $C_4$ -alkenylen,  $C_2$ - $C_4$ -alkynylen, O, O-( $C_1$ - $C_4$ -alkylen), S, S-( $C_1$ - $C_4$ -alkylen),  $NR^{54}$ ,  $NR^{54}$ -( $C_1$ - $C_4$ -alkylen) and a bond,

X is selected from the group consisting of CO, CO-O,  $SO_2$ ,  $NR^{54}$ ,  $NR^{54}$ -CO,  $NR^{54}$ - $SO_2$ , CO- $NR^{58}$  and a bond,

25 Y is  $C_1$ - $C_6$ -alkylen,  $C_2$ - $C_6$ -alkenylen,  $C_2$ - $C_6$ -alkynylen, or a bond,

Z is selected from the group consisting of hydrogen, E, O- $R^{52}$ ,  $NR^{51}R^{52}$ , S- $R^{52}$ , where

E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, said ring may comprise up to two oxo groups, and  
30 may be substituted by radicals  $R^{55}$ ,  $R^{56}$ ,  $R^{57}$  and/or up to three radicals  $R^{53}$  and,

$R^{51}$  at each occurrence is independently selected from the group consisting of hydrogen,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, phenyl and  $C_1$ - $C_4$ -alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals  $R^{53}$ ,  
35

$R^{52}$  at each occurrence is independently selected from the group consisting of

hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, E and C<sub>1</sub>-C<sub>4</sub>-alkylen-E,

5 R<sup>53</sup> at each occurrence is independently selected from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

10 R<sup>54</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl and C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R<sup>59</sup>,

15 R<sup>55</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl, C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the ring may be substituted by up to two radicals R<sup>60</sup>, and OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, O-phenyl, O-C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

R<sup>56</sup> is a group Q<sup>1</sup>-Q<sup>2</sup>-Q<sup>3</sup>, where

20 Q<sup>1</sup> is selected from the group consisting of a bond, C<sub>1</sub>-C<sub>4</sub>-alkylen, C<sub>2</sub>-C<sub>4</sub>-alkenylen, C<sub>2</sub>-C<sub>4</sub>-alkynylen, C<sub>1</sub>-C<sub>4</sub>-alkylen-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), N(C<sub>1</sub>-C<sub>4</sub>-alkyl), C<sub>1</sub>-C<sub>4</sub>-alkylen-NH, NH, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-C<sub>1</sub>-C<sub>4</sub>-alkylen, NH-C<sub>1</sub>-C<sub>4</sub>-alkylen, O, C<sub>1</sub>-C<sub>4</sub>-alkylen-O, O-C<sub>1</sub>-C<sub>4</sub>-alkylen, CO-NH, CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO, CO, SO<sub>2</sub>, SO, S, O, SO<sub>2</sub>-NH, SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-SO<sub>2</sub>, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-SO<sub>2</sub>, O-CO-NH, O-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO-O, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-O, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-NH, and NH-CO-NH,

Q<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub>-alkylen, C<sub>2</sub>-C<sub>4</sub>-alkenylen, C<sub>2</sub>-C<sub>4</sub>-alkynylen, and a bond,

30 Q<sup>3</sup> is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups and may be substituted by the radicals R<sup>63</sup>, R<sup>64</sup> and/or R<sup>65</sup>,

35 R<sup>57</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, phenyl, C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, COOH, CO-O-C<sub>1</sub>-C<sub>4</sub>-alkyl, CONH<sub>2</sub>, CO-NH-C<sub>1</sub>-C<sub>4</sub>-alkyl, CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>, CO-C<sub>1</sub>-C<sub>4</sub>-alkyl, CH<sub>2</sub>-NH<sub>2</sub>,

CH<sub>2</sub>-NH-C<sub>1</sub>-C<sub>4</sub>-alkyl and CH<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

5 R<sup>58</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl and C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R<sup>62</sup>,

10 R<sup>59</sup>, R<sup>60</sup> and R<sup>62</sup> at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,


15 R<sup>63</sup>, R<sup>64</sup> and R<sup>65</sup> at each occurrence are independently selected of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, O-phenyl, O-C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, phenyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

20 R<sup>6</sup> and R<sup>7</sup> at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, O-phenyl, O-C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, phenyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof.

25 5. (Previously Presented) The compound of claim 4, wherein B is selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine, pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline.

6. (Previously Presented) A compound of the formula (III),



in which

D is an aromatic heteromonocyclic, or an aromatic or partially aromatic heterobicyclic ring,

5

where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups,

and D may be substituted by radicals  $R^{21}$ ,  $R^{22}$  and/or  $R^{23}$ ,

10

G is an aromatic heteromonocyclic, aromatic or partially aromatic heterobicyclic ring,

where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups and

15

G may be substituted by radicals  $R^{71}$ ,  $R^{72}$  and/or  $R^{73}$ ,

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$ ,  $R^{71}$ ,  $R^{72}$  and  $R^{73}$  at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , OH, O- $C_1$ - $C_4$ -alkyl, O-phenyl, O- $C_1$ - $C_4$ -alkylen-phenyl, phenyl,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $NH_2$ ,  $NH(C_1$ - $C_4$ -alkyl) and  $N(C_1$ - $C_4$ -alkyl) $_2$ , morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-piperazin-1-yl, 4- $(C_1$ - $C_4$ -alkyl)-piperazin-1-yl,

20

$R^3$  and  $R^4$  at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , OH, O- $C_1$ - $C_4$ -alkyl, O-phenyl, O- $C_1$ - $C_4$ -alkylen-phenyl, phenyl,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $NH_2$ ,  $NH(C_1$ - $C_4$ -alkyl) and  $N(C_1$ - $C_4$ -alkyl) $_2$ , or

25



$R^3$  and  $R^4$  are connected to give  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ ,  $-(\text{CH}_2)_4-$  or  $-(\text{CH}_2)_3-$ ,

$R^5$  is a radical (W)-(X)-(Y)-Z, where

5 W is selected from the group consisting of  $\text{C}_1$ - $\text{C}_4$ -alkylen,  $\text{C}_2$ - $\text{C}_4$ -alkenylen,  $\text{C}_2$ - $\text{C}_4$ -alkynylen, O, O-( $\text{C}_1$ - $\text{C}_4$ -alkylen), S, S-( $\text{C}_1$ - $\text{C}_4$ -alkylen),  $\text{NR}^{54}$ ,  $\text{NR}^{54}$ -( $\text{C}_1$ - $\text{C}_4$ -alkylen) and a bond,

X is selected from the group consisting of CO, CO-O,  $\text{SO}_2$ ,  $\text{NR}^{54}$ ,  $\text{NR}^{54}$ -CO,  $\text{NR}^{54}$ - $\text{SO}_2$ , CO- $\text{NR}^{58}$  and a bond,

10 Y is  $\text{C}_1$ - $\text{C}_6$ -alkylen,  $\text{C}_2$ - $\text{C}_6$ -alkenylen,  $\text{C}_2$ - $\text{C}_6$ -alkynylen, or a bond,

Z is selected from the group consisting of hydrogen, E, O- $\text{R}^{52}$ ,  $\text{NR}^{51}\text{R}^{52}$ , S- $\text{R}^{52}$ , where

E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups, and E  
15 may be substituted by radicals  $\text{R}^{55}$ ,  $\text{R}^{56}$ ,  $\text{R}^{57}$  and/or up to three radicals  $\text{R}^{53}$ ,

$\text{R}^{51}$  at each occurrence is independently selected from the group consisting of hydrogen,  $\text{C}_1$ - $\text{C}_6$ -alkyl,  $\text{C}_2$ - $\text{C}_6$ -alkenyl,  $\text{C}_2$ - $\text{C}_6$ -alkynyl, phenyl and  $\text{C}_1$ - $\text{C}_4$ -alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals  $\text{R}^{53}$ ,  
20

$\text{R}^{52}$  at each occurrence is independently selected from the group consisting of hydrogen,  $\text{C}_1$ - $\text{C}_6$ -alkyl,  $\text{C}_2$ - $\text{C}_6$ -alkenyl,  $\text{C}_2$ - $\text{C}_6$ -alkynyl, E and  $\text{C}_1$ - $\text{C}_4$ -alkylen-E,

$\text{R}^{53}$  at each occurrence is independently selected from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{NO}_2$ , OH, O- $\text{C}_1$ - $\text{C}_4$ -alkyl,  $\text{C}_1$ - $\text{C}_6$ -alkyl,  $\text{C}_2$ - $\text{C}_6$ -alkenyl,  $\text{C}_2$ - $\text{C}_6$ -alkynyl,  $\text{NH}_2$ ,  $\text{NH}(\text{C}_1$ - $\text{C}_4$ -alkyl) and  $\text{N}(\text{C}_1$ - $\text{C}_4$ -alkyl)<sub>2</sub>,  
25

$\text{R}^{54}$  at each occurrence is independently selected from the group consisting of hydrogen,  $\text{C}_1$ - $\text{C}_6$ -alkyl,  $\text{C}_2$ - $\text{C}_6$ -alkenyl,  $\text{C}_2$ - $\text{C}_6$ -alkynyl, phenyl and  $\text{C}_1$ - $\text{C}_4$ -alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals  $\text{R}^{59}$ ,  
30

$\text{R}^{55}$  at each occurrence is independently selected from the group consisting of hydrogen,  $\text{C}_1$ - $\text{C}_6$ -alkyl,  $\text{C}_2$ - $\text{C}_6$ -alkenyl,  $\text{C}_2$ - $\text{C}_6$ -alkynyl, phenyl,  $\text{C}_1$ - $\text{C}_4$ -alkylen-phenyl, where the ring may be substituted by up to two radicals  $\text{R}^{60}$ , and OH, O- $\text{C}_1$ - $\text{C}_4$ -alkyl, O-phenyl, O- $\text{C}_1$ - $\text{C}_4$ -alkylen-phenyl,  $\text{NH}_2$ ,  $\text{NH}(\text{C}_1$ - $\text{C}_4$ -alkyl) and  $\text{N}(\text{C}_1$ - $\text{C}_4$ -alkyl)<sub>2</sub>,  
35

R<sup>56</sup> is a group Q<sup>1</sup>-Q<sup>2</sup>-Q<sup>3</sup>, where

5 Q<sup>1</sup> is selected from the group consisting of a bond, C<sub>1</sub>-C<sub>4</sub>-alkylen, C<sub>2</sub>-C<sub>4</sub>-alkenylen, C<sub>2</sub>-C<sub>4</sub>-alkynylen, C<sub>1</sub>-C<sub>4</sub>-alkylen-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), N(C<sub>1</sub>-C<sub>4</sub>-alkyl), C<sub>1</sub>-C<sub>4</sub>-alkylen-NH, NH, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-C<sub>1</sub>-C<sub>4</sub>-alkylen, NH-C<sub>1</sub>-C<sub>4</sub>-alkylen, O, C<sub>1</sub>-C<sub>4</sub>-alkylen-O, O-C<sub>1</sub>-C<sub>4</sub>-alkylen, CO-NH, CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO, CO, SO<sub>2</sub>, SO, S, O, SO<sub>2</sub>-NH, SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-SO<sub>2</sub>, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-SO<sub>2</sub>, O-CO-NH, O-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO-O, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-O, N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), NH-CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl), N(C<sub>1</sub>-C<sub>4</sub>-alkyl)-CO-NH, and NH-CO-NH,

Q<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub>-alkylen, C<sub>2</sub>-C<sub>4</sub>-alkenylen, C<sub>2</sub>-C<sub>4</sub>-alkynylen, and a bond,

15 Q<sup>3</sup> is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups and may be substituted by the radicals R<sup>63</sup>, R<sup>64</sup> and/or R<sup>65</sup>,

20 R<sup>57</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, phenyl, C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, COOH, CO-O-C<sub>1</sub>-C<sub>4</sub>-alkyl, CONH<sub>2</sub>, CO-NH-C<sub>1</sub>-C<sub>4</sub>-alkyl, CO-N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>, CO-C<sub>1</sub>-C<sub>4</sub>-alkyl, CH<sub>2</sub>-NH<sub>2</sub>, CH<sub>2</sub>-NH-C<sub>1</sub>-C<sub>4</sub>-alkyl and CH<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

25 R<sup>58</sup> at each occurrence is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl and C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R<sup>62</sup>,

30 R<sup>59</sup>, R<sup>60</sup> and R<sup>62</sup> at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

35 R<sup>63</sup>, R<sup>64</sup> and R<sup>65</sup> at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, OH, O-C<sub>1</sub>-C<sub>4</sub>-alkyl, O-phenyl, O-C<sub>1</sub>-C<sub>4</sub>-alkylen-phenyl, phenyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>-alkyl) and N(C<sub>1</sub>-C<sub>4</sub>-alkyl)<sub>2</sub>,

and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof.

7. (Previously Presented) The compound of claim 6, wherein D is selected from the group consisting of aromatic heteromonocyclic and aromatic heterobicyclic systems comprising 1 or 2 heteroatoms, where one of the 2 heteroatoms is nitrogen.

8. (Previously Presented) The compound of claim 6, wherein D is selected from the group consisting of benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline, quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene, benzofuran and furan.

9. (Currently Amended) The compound of ~~any of claims~~ claim 6 [to 8] wherein G is selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine, pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline.

10. (Currently Amended) A [medicament] pharmaceutical composition comprising a compound as claimed in ~~any of claims~~ claim 1 [to 9] and a pharmaceutically acceptable carrier.

11. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the control and/or prophylaxis of various~~ A method for the therapeutic and/or prophylactic treatment of a mammal having a vasopressin-dependent or oxytocin-dependent [diseases] disease comprising administering an effective amount of a compound of claim 1 to a mammal in need of such treatment.

12. (Cancel)

13. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of depressions~~ A method as in claim 11 where the disease is depression and/or a bipolar [disorders] disorder such as, for example, dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders.

14. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of~~ A method as in claim 11 where the disease is anxiety and/or stress-related

disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia.

15. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of~~ A method as in claim 11 where the disease is a memory [disorders] disorder and/or Alzheimer's disease.

16. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of psychoses~~ A method as in claim 11 wherein the disease is psychosis and/or a psychotic [disorders] disorder.

17. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of~~ A method as in claim 11 where the disease is [Cushing's] cushing's syndrome.

18. (New) A pharmaceutical composition comprising a compound as claimed in claim 6 and a pharmaceutically acceptable carrier.

19. (New) A method for the therapeutic and/or prophylactic treatment of a mammal having a vasopressin-dependent or oxytocin-dependent disease comprising administering an effective amount of a compound of claim 6 to a mammal in need of such treatment.

20. (New) A method as in claim 19 where the disease is depression and/or a bipolar disorder such as, for example, dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders.

21. (New) A method as in claim 19 where the disease is anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia.

22. (New) A method as in claim 19 where the disease is a memory disorder and/or Alzheimer's disease.

23. (New) A method as in claim 19 wherein the disease is psychosis and/or a psychotic disorder.

24. (New) A method as in claim 19 where the disease is cushing's syndrome.

25. (New) A pharmaceutical composition comprising a compound as claimed in claim 4 and a pharmaceutically acceptable carrier.
- 5 26. (New) A method for the therapeutic and/or prophylactic treatment of a mammal having a vasopressin-dependent or oxytocin-dependent disease comprising administering an effective amount of a compound of claim 4 to a mammal in need of such treatment.
- 10 27. (New) A method as in claim 26 where the disease is depression and/or a bipolar disorder such as, for example, dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders.
- 15 28. (New) A method as in claim 26 where the disease is anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia.
- 20 29. (New) A method as in claim 26 where the disease is a memory disorder and/or Alzheimer's disease.
30. (New) A method as in claim 26 wherein the disease is psychosis and/or a psychotic disorder.
31. (New) A method as in claim 26 where the disease is cushing's syndrome.